FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2944318130> ?p ?o ?g. }

• W2944318130 endingPage "1557" @default.
• W2944318130 startingPage "1547" @default.
• W2944318130 abstract "PURPOSE Novel sensitive methods for early detection of relapse and for monitoring therapeutic efficacy may have a huge impact on risk stratification, treatment, and ultimately outcome for patients with bladder cancer. We addressed the prognostic and predictive impact of ultra-deep sequencing of cell-free DNA in patients before and after cystectomy and during chemotherapy. PATIENTS AND METHODS We included 68 patients with localized advanced bladder cancer. Patient-specific somatic mutations, identified by whole-exome sequencing, were used to assess circulating tumor DNA (ctDNA) by ultra-deep sequencing (median, 105,000×) of plasma DNA. Plasma samples (n = 656) were procured at diagnosis, during chemotherapy, before cystectomy, and during surveillance. Expression profiling was performed for tumor subtype and immune signature analyses. RESULTS Presence of ctDNA was highly prognostic at diagnosis before chemotherapy (hazard ratio, 29.1; P = .001). After cystectomy, ctDNA analysis correctly identified all patients with metastatic relapse during disease monitoring (100% sensitivity, 98% specificity). A median lead time over radiographic imaging of 96 days was observed. In addition, for high-risk patients (ctDNA positive before or during treatment), the dynamics of ctDNA during chemotherapy was associated with disease recurrence ( P = .023), whereas pathologic downstaging was not. Analysis of tumor-centric biomarkers showed that mutational processes (signature 5) were associated with pathologic downstaging ( P = .024); however, no significant correlation for tumor subtypes, DNA damage response mutations, and other biomarkers was observed. Our results suggest that ctDNA analysis is better associated with treatment efficacy compared with other available methods. CONCLUSION ctDNA assessment for early risk stratification, therapy monitoring, and early relapse detection in bladder cancer is feasible and provides a basis for clinical studies that evaluate early therapeutic interventions." @default.
• W2944318130 created "2019-05-16" @default.
• W2944318130 creator A5006030834 @default.
• W2944318130 creator A5006726266 @default.
• W2944318130 creator A5007467209 @default.
• W2944318130 creator A5011068249 @default.
• W2944318130 creator A5011286209 @default.
• W2944318130 creator A5014868163 @default.
• W2944318130 creator A5019975916 @default.
• W2944318130 creator A5020017588 @default.
• W2944318130 creator A5022294693 @default.
• W2944318130 creator A5025067609 @default.
• W2944318130 creator A5026616543 @default.
• W2944318130 creator A5026662006 @default.
• W2944318130 creator A5028662238 @default.
• W2944318130 creator A5034866415 @default.
• W2944318130 creator A5035721545 @default.
• W2944318130 creator A5038793637 @default.
• W2944318130 creator A5045532538 @default.
• W2944318130 creator A5048740673 @default.
• W2944318130 creator A5048804324 @default.
• W2944318130 creator A5050758135 @default.
• W2944318130 creator A5050955986 @default.
• W2944318130 creator A5055440728 @default.
• W2944318130 creator A5057373226 @default.
• W2944318130 creator A5057699016 @default.
• W2944318130 creator A5057852307 @default.
• W2944318130 creator A5059305173 @default.
• W2944318130 creator A5059620845 @default.
• W2944318130 creator A5064275932 @default.
• W2944318130 creator A5065344327 @default.
• W2944318130 creator A5067488577 @default.
• W2944318130 creator A5067930944 @default.
• W2944318130 creator A5085613881 @default.
• W2944318130 creator A5090571571 @default.
• W2944318130 creator A5091711361 @default.
• W2944318130 date "2019-06-20" @default.
• W2944318130 modified "2023-10-13" @default.
• W2944318130 title "Early Detection of Metastatic Relapse and Monitoring of Therapeutic Efficacy by Ultra-Deep Sequencing of Plasma Cell-Free DNA in Patients With Urothelial Bladder Carcinoma" @default.
• W2944318130 cites W2033775272 @default.
• W2944318130 cites W2084176110 @default.
• W2944318130 cites W2103725052 @default.
• W2944318130 cites W2122538591 @default.
• W2944318130 cites W2123431502 @default.
• W2944318130 cites W2131178190 @default.
• W2944318130 cites W2135640630 @default.
• W2944318130 cites W2154018281 @default.
• W2944318130 cites W2173105601 @default.
• W2944318130 cites W2281315182 @default.
• W2944318130 cites W2317091748 @default.
• W2944318130 cites W2334047202 @default.
• W2944318130 cites W2343368549 @default.
• W2944318130 cites W2460179076 @default.
• W2944318130 cites W2462649057 @default.
• W2944318130 cites W2517491133 @default.
• W2944318130 cites W2533194337 @default.
• W2944318130 cites W2568815887 @default.
• W2944318130 cites W2570341714 @default.
• W2944318130 cites W2581231749 @default.
• W2944318130 cites W2604535399 @default.
• W2944318130 cites W2607031352 @default.
• W2944318130 cites W2608738563 @default.
• W2944318130 cites W2622114026 @default.
• W2944318130 cites W2734508763 @default.
• W2944318130 cites W2754701143 @default.
• W2944318130 cites W2757841853 @default.
• W2944318130 cites W2767034994 @default.
• W2944318130 cites W2883787611 @default.
• W2944318130 cites W2899311685 @default.
• W2944318130 cites W2899540665 @default.
• W2944318130 cites W31906959 @default.
• W2944318130 doi "https://doi.org/10.1200/jco.18.02052" @default.
• W2944318130 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31059311" @default.
• W2944318130 hasPublicationYear "2019" @default.
• W2944318130 type Work @default.
• W2944318130 sameAs 2944318130 @default.
• W2944318130 citedByCount "266" @default.
• W2944318130 countsByYear W29443181302019 @default.
• W2944318130 countsByYear W29443181302020 @default.
• W2944318130 countsByYear W29443181302021 @default.
• W2944318130 countsByYear W29443181302022 @default.
• W2944318130 countsByYear W29443181302023 @default.
• W2944318130 crossrefType "journal-article" @default.
• W2944318130 hasAuthorship W2944318130A5006030834 @default.
• W2944318130 hasAuthorship W2944318130A5006726266 @default.
• W2944318130 hasAuthorship W2944318130A5007467209 @default.
• W2944318130 hasAuthorship W2944318130A5011068249 @default.
• W2944318130 hasAuthorship W2944318130A5011286209 @default.
• W2944318130 hasAuthorship W2944318130A5014868163 @default.
• W2944318130 hasAuthorship W2944318130A5019975916 @default.
• W2944318130 hasAuthorship W2944318130A5020017588 @default.
• W2944318130 hasAuthorship W2944318130A5022294693 @default.
• W2944318130 hasAuthorship W2944318130A5025067609 @default.
• W2944318130 hasAuthorship W2944318130A5026616543 @default.
• W2944318130 hasAuthorship W2944318130A5026662006 @default.
• W2944318130 hasAuthorship W2944318130A5028662238 @default.
• W2944318130 hasAuthorship W2944318130A5034866415 @default.
• W2944318130 hasAuthorship W2944318130A5035721545 @default.

• next